Literature DB >> 29094227

Down-regulation of Noggin and miR-138 coordinately promote osteogenesis of mesenchymal stem cells.

Xing-Kun Sun1,2,3, Jin Zhou1, Lei Zhang4, Tian Ma5, Yu-Han Wang6, Yan-Mei Yang7, Yan-Ting Tang8, Hong Li9, Li-Jun Wang10.   

Abstract

Mesenchymal stem cells (MSCs) can differentiate to osteocytes under suitable conditions. In recent years, micro-nucleotides have been progressively used to modulate gene expression in cells due to the consideration of safety. Our present study aimed to investigate whether co-delivery of Noggin-siRNA and antimiR-138 enhances the osteogenic effect of MSCs. Using a murine MSC line, C3H/10T1/2 cells, the delivery efficiency of Noggin-siRNA and antimiR-138 into MSCs was evaluated by quantitative real-time polymerase chain reaction (qRT-PCR). Cell phenotype and proliferation capacity was assessed by flow cytometry and MTT assay respectively. The osteogenesis of MSCs was tested by Alkaline Phosphatase (ALP) staining, qRT-PCR, and western blot analyses. Our results demonstrated that the expression of Noggin and miR-138 were significantly silenced in MSCs by Noggin-siRNA and/or antimiR-138 delivery, while the phenotype and proliferation capacity of MSCs were not affected. Down-regulation of Noggin and miR-138 cooperatively promoted osteogenic differentiation of MSCs. The ALP positive cells reached about 83.57 ± 10.18%. Compared with single delivery, the expression of osteogenic related genes, such as Alp, Col-1, Bmp2, Ocn and Runx2, were the highest in cells with co-delivery of the two oligonucleotides. Moreover, the protein level of RUNX2, and the ratios of pSMAD1/5/SMAD1/5 and pERK1/2/ERK1/2 were significantly increased. The activation of Smad, Erk signaling may constitute the underlying mechanism of the enhanced osteogenesis process. Taken together, our study provides a safe strategy for the clinical rehabilitation application of MSCs in skeletal deficiency.

Entities:  

Keywords:  AntimiR-138; MSCs; Mesenchymal stem cells; Noggin-siRNA; Osteogenic effect

Mesh:

Substances:

Year:  2017        PMID: 29094227     DOI: 10.1007/s10735-017-9740-5

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  43 in total

1.  Dimorphic effects of Notch signaling in bone homeostasis.

Authors:  Feyza Engin; Zhenqiang Yao; Tao Yang; Guang Zhou; Terry Bertin; Ming Ming Jiang; Yuqing Chen; Lisa Wang; Hui Zheng; Richard E Sutton; Brendan F Boyce; Brendan Lee
Journal:  Nat Med       Date:  2008-02-24       Impact factor: 53.440

Review 2.  Progress and Prospects: genetic treatments for disorders of bones and joints.

Authors:  C H Evans; S C Ghivizzani; P D Robbins
Journal:  Gene Ther       Date:  2009-08       Impact factor: 5.250

Review 3.  Non-viral nucleic acid delivery: key challenges and future directions.

Authors:  Mahmoud Elsabahy; Adil Nazarali; Marianna Foldvari
Journal:  Curr Drug Deliv       Date:  2011-05       Impact factor: 2.565

Review 4.  RNA interference therapy via functionalized scaffolds.

Authors:  Michael Monaghan; Abhay Pandit
Journal:  Adv Drug Deliv Rev       Date:  2011-01-15       Impact factor: 15.470

5.  MicroRNA expression during osteogenic differentiation of human multipotent mesenchymal stromal cells from bone marrow.

Authors:  Jie Gao; Tongtao Yang; Jianwei Han; Kang Yan; Xiuchun Qiu; Yong Zhou; Qingyu Fan; Baoan Ma
Journal:  J Cell Biochem       Date:  2011-07       Impact factor: 4.429

Review 6.  Nonviral cancer gene therapy: Delivery cascade and vector nanoproperty integration.

Authors:  Zhuxian Zhou; Xiangrui Liu; Dingcheng Zhu; Yue Wang; Zhen Zhang; Xuefei Zhou; Nasha Qiu; Xuesi Chen; Youqing Shen
Journal:  Adv Drug Deliv Rev       Date:  2017-08-01       Impact factor: 15.470

7.  Interaction of cholesterol-conjugated ionizable amino lipids with biomembranes: lipid polymorphism, structure-activity relationship, and implications for siRNA delivery.

Authors:  Jingtao Zhang; Haihong Fan; Dorothy A Levorse; Louis S Crocker
Journal:  Langmuir       Date:  2011-06-29       Impact factor: 3.882

8.  Chitosan-graft-(PEI-β-cyclodextrin) copolymers and their supramolecular PEGylation for DNA and siRNA delivery.

Authors:  Yuan Ping; Chengde Liu; Zhongxing Zhang; Kerh Li Liu; Jianhai Chen; Jun Li
Journal:  Biomaterials       Date:  2011-08-15       Impact factor: 12.479

Review 9.  Runx2 and microRNA regulation in bone and cartilage diseases.

Authors:  Weiwei Zhao; Shanxing Zhang; Baoli Wang; Jian Huang; William W Lu; Di Chen
Journal:  Ann N Y Acad Sci       Date:  2016-08-15       Impact factor: 5.691

10.  Delivery of siRNA via cationic Sterosomes to enhance osteogenic differentiation of mesenchymal stem cells.

Authors:  Zhong-Kai Cui; Jiabing Fan; Soyon Kim; Olga Bezouglaia; Armita Fartash; Benjamin M Wu; Tara Aghaloo; Min Lee
Journal:  J Control Release       Date:  2015-08-21       Impact factor: 9.776

View more
  6 in total

1.  CGRP gene-modified rBMSCs show better osteogenic differentiation capacity in vitro.

Authors:  Xijiao Yu; Shuang Liu; Hui Chen; Xinyu Zhao; Xue Chen; Yi Du; Shu Li
Journal:  J Mol Histol       Date:  2018-05-30       Impact factor: 2.611

2.  Correlation of TERT and Stem Cell Markers in the Context of Human Breast Cancer.

Authors:  Umar Wazir; Mona M A W Orakzai; Tracey Amanda Martin; Wen G Jiang; Kefah Mokbel
Journal:  Cancer Genomics Proteomics       Date:  2019 Mar-Apr       Impact factor: 4.069

3.  Semaphorin 3A promotes osteogenic differentiation of BMSC from type 2 diabetes mellitus rats.

Authors:  Qiao Qiao; Xiaoru Xu; Yingliang Song; Shuang Song; Wenzhong Zhu; Fenglan Li
Journal:  J Mol Histol       Date:  2018-05-17       Impact factor: 2.611

4.  miR-484/MAP2/c-Myc-positive regulatory loop in glioma promotes tumor-initiating properties through ERK1/2 signaling.

Authors:  Renhui Yi; Jiugeng Feng; Shaochun Yang; Xiaoyu Huang; Yuanyuan Liao; Zheng Hu; Muyun Luo
Journal:  J Mol Histol       Date:  2018-02-26       Impact factor: 2.611

Review 5.  Mesenchymal Stem Cells: Allogeneic MSC May Be Immunosuppressive but Autologous MSC Are Dysfunctional in Lupus Patients.

Authors:  Rui-Juan Cheng; An-Ji Xiong; Yan-Hong Li; Shu-Yue Pan; Qiu-Ping Zhang; Yi Zhao; Yi Liu; Tony N Marion
Journal:  Front Cell Dev Biol       Date:  2019-11-15

6.  MiR-138-5p targets RUNX2 to inhibit osteogenic differentiation of aortic valve interstitial cells via Wnt/β-catenin signaling pathway.

Authors:  Fei Yan; Qiang Huo; Weimin Zhang; Tingting Wu; Daniyaer Dilimulati; Lin Shi
Journal:  BMC Cardiovasc Disord       Date:  2022-02-02       Impact factor: 2.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.